STOCK TITAN

Director Matthew Strobeck to leave QuidelOrtho (NASDAQ: QDEL) board

Filing Impact
(Moderate)
Filing Sentiment
(Neutral)
Form Type
8-K

Rhea-AI Filing Summary

QuidelOrtho Corporation reported that board member Matthew W. Strobeck has decided not to stand for re-election at the company’s 2026 annual stockholders meeting. He will remain on the board until that meeting, after which the board size will decrease from eleven to ten directors. The company states that his decision is due to other professional commitments and not any dispute or disagreement with the company, its board, or management over operations, policies, or practices.

Positive

  • None.

Negative

  • None.
QuidelOrtho Corp false 0001906324 0001906324 2026-01-30 2026-01-30
 
 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

 

 

FORM 8-K

 

 

CURRENT REPORT

PURSUANT TO SECTION 13 OR 15(d)

OF THE SECURITIES EXCHANGE ACT OF 1934

Date of Report (Date of earliest event reported): January 30, 2026

 

 

QUIDELORTHO CORPORATION

(Exact name of Registrant as specified in its Charter)

 

 

 

Delaware   001-41409   87-4496285
(State or other jurisdiction
of incorporation)
 

(Commission

File Number)

  (IRS Employer
Identification No.)

9975 Summers Ridge Road, San Diego, California 92121

(Address of principal executive offices, including zip code)

(858) 552-1100

(Registrant’s telephone number, including area code)

N/A

(Former name or former address, if changed since last report)

 

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the Registrant under any of the following provisions (see General Instruction A.2. below):

 

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class

 

Trading

symbol(s)

 

Name of each exchange
on which registered

Common Stock, $0.001 Par Value   QDEL   The Nasdaq Stock Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

 
 


Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

On January 30, 2026, Matthew W. Strobeck, a member of the board of directors (the “Board”) of QuidelOrtho Corporation (the “Company”), provided notice to the Board of his decision not to stand for re-election at the Company’s 2026 annual stockholders meeting (the “Annual Meeting”). Dr. Strobeck will continue to serve as a Board member until the Annual Meeting, at which point a reduction in the size of the Board from eleven to ten directors will be effective. Dr. Strobeck’s decision not to stand for re-election was due to other professional commitments and was not the result of any dispute or disagreement with the Company, the Board or management on any matter relating to the Company’s operations, policies or practices. The Company and the Board extend their gratitude to Dr. Strobeck for his eight years of service on the Board and for his contributions during his tenure as a director.


SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date: February 5, 2026

 

QUIDELORTHO CORPORATION
By:  

/s/ Michelle A. Hodges

Name:   Michelle A. Hodges
Its:   Secretary

FAQ

What did QuidelOrtho (QDEL) disclose in this 8-K filing?

QuidelOrtho disclosed that director Matthew W. Strobeck will not stand for re-election at the 2026 annual stockholders meeting. He will serve until the meeting, after which the board will be reduced from eleven to ten directors.

Who is the QuidelOrtho (QDEL) director leaving the board?

Director Matthew W. Strobeck has informed QuidelOrtho’s board that he will not stand for re-election at the 2026 annual stockholders meeting. He has served on the board for eight years and will continue as a director until that meeting.

When will Matthew W. Strobeck step down from QuidelOrtho’s board?

Matthew W. Strobeck will step down at QuidelOrtho’s 2026 annual stockholders meeting. He will continue serving as a director until that meeting, at which time his term ends and the board size will be reduced from eleven to ten members.

Why is Matthew W. Strobeck not standing for re-election at QuidelOrtho (QDEL)?

Matthew W. Strobeck is not standing for re-election due to other professional commitments. QuidelOrtho states his decision is not the result of any dispute or disagreement with the company, its board, or management regarding operations, policies, or practices.

How will QuidelOrtho’s board size change after the 2026 annual meeting?

After the 2026 annual stockholders meeting, QuidelOrtho’s board size will decrease from eleven to ten directors. This change will take effect when Matthew W. Strobeck’s term ends, following his decision not to stand for re-election at the meeting.

Did QuidelOrtho (QDEL) report any disagreement related to the director’s departure?

QuidelOrtho reported that Matthew W. Strobeck’s decision not to stand for re-election was not due to any dispute or disagreement. The company states there was no disagreement over its operations, policies, or practices with the board or management.
Quidel

NASDAQ:QDEL

QDEL Rankings

QDEL Latest News

QDEL Latest SEC Filings

QDEL Stock Data

1.99B
66.81M
0.92%
117.99%
11.25%
Medical Devices
In Vitro & in Vivo Diagnostic Substances
Link
United States
SAN DIEGO